Mölnlycke’s science-based targets validated
The Science Based Targets initiative (SBTi) has validated that the greenhouse gas (GHG) emission reduction targets submitted by Mölnlycke Health Care conform to the SBTi criteria and recommendations and are aligned with the 1.5°C trajectory. This is the next step towards Mölnlycke’s ambition to help decarbonise healthcare.

Today, Mölnlycke Health Care, a world leading MedTech company, announces that its near-term GHG emission reduction targets submitted to the SBTi have been validated and deemed to be compliant with all applicable requirements.
Specifically, Mölnlycke has committed to reduce absolute scope 1 and 2 GHG emissions by 50% by 2030, from a 2021 base year, to increase active annual sourcing of renewable electricity from 23% in 2021 to 100% by 2024, and to continue sourcing of 100% renewable electricity through 2030.
Furthermore, the company committed to reducing absolute scope 3 GHG emissions from purchased goods and services, fuel and energy related activities, upstream transportation and distribution and waste generated in operations by 20% by 2028, from a 2021 base year.
Finally, Mölnlycke committed that 63% of its suppliers by emissions covering purchased goods and services, capital goods, and upstream transportation and distribution, will have set science-based targets by 2028.
“SBTi validation is a key milestone in our long-term strategy to help decarbonise the healthcare sector” said Zlatko Rihter, Chief Executive Officer, Mölnlycke Health Care. “We are committed to reach Net Zero by 2050 at the latest, and are accelerating the process of minimising both the direct and indirect impact of our operations on the planet.”
Mölnlycke stands well poised for reaching the targets through a series of impact initiatives:
- For scope 1 and scope 2 targets concerning our own manufacturing facilities and headquarters, Mölnlycke’s implementation of a renewable electricity roadmap is well underway and will be achieved through a combination of virtual Power Purchase Agreements, renewable energy certificates (RECs) and investments in higher additionality energy sources, e.g. photovoltaic systems.
- For scope 3 and the supplier engagement target, Mölnlycke has already initiated activities under the Sustainable Procurement framework aimed at increasing collaboration with suppliers to bring innovation in raw materials and improved transportation routes that are needed to transition to a low-carbon economy. Mölnlycke are ensuring a defined set of suppliers commit to reducing emissions through the SBTi.
The official information on Mölnlycke’s commitment can be found here.
About SBTi
The Science Based Targets Initiative (SBTi) is a global partnership made up of leading climate organisations, including the Carbon Disclosure Project, the United Nations Global Compact, World Resources Institute (WRI) and the World Wide Fund for Nature (WWF). The SBTi defines and promotes best practice in emissions reductions and Net-zero targets in line with science. It provides technical assistance and expert resources to companies that set science-based targets, to ensure their alignment with the Paris Agreement, to limit global warming to 1.5C.
Latest press releases
Go to Media room-
Mölnlycke Health Care inaugurates new global headquarters at GoCo Health Innovation City
Gothenburg, Sweden. 21 May 2025 – Mölnlycke Health Care, a global leader in MedTech, has officially opened its new global headquarters at GoCo Health Innovation City in Gothenburg, Sweden—a major milestone in its journey to drive sustainable healthcare innovation.
-
Mölnlycke Health Care’s long-term target to reach net zero emissions validated by Science Based Targets initiative
Gothenburg, Sweden. 13 May, 2025. Mölnlycke’s long-term net zero greenhouse gas (GHG) emission reduction targets have been validated by the Science Based Targets initiative (SBTi), following prior validation of the company’s near-term GHG emission reduction targets.
-
Mölnlycke Health Care supports the Wound Care Collaborative Community initiative to improve wound dressing standards
Gothenburg, Sweden. May 02, 2025. The Wound Care Collaborative Community (WCCC) is leading a groundbreaking initiative looking to develop a standardised pre-clinical testing framework for wound dressings.
-
Mölnlycke Health Care publishes Annual report for 2024
Gothenburg, Sweden. 1 April 2025. Today Mölnlycke Health Care has published its Annual report for 2024, including the sustainability report.
-
New study demonstrates the potential benefits of dressing regime improvements in delivering value-based chronic wound care
-
Mölnlycke Health Care announces USD 8 million investment in diabetic foot ulcer management system company Siren
-
Mölnlycke Health Care reaches 100% renewable electricity target
Mölnlycke, a world leading MedTech company, has secured 100% renewable electricity for all its established and new manufacturing sites and its headquarters, reaching its first near-term SBTi (Science Based Targets initiative)-validated target.
-
Mölnlycke Health Care expands investment in Tamer Mölnlycke Care joint venture
Mölnlycke Health Care, a world leading MedTech company, has expanded its commitment to operations in the Middle East by extending its stake from 33.3% to 60% to become majority shareholder in Tamer Mölnlycke Care - a joint venture with Tamer Group, the market leader in healthcare distribution in the Kingdom of Saudi Arabia.
-
Mölnlycke Health Care agrees to acquire leading wound cleansing manufacturer to consolidate its position as global leader in wound care
Mölnlycke signed an agreement to acquire P.G.F. Industry Solutions GmbH, the manufacturer of Granudacyn®, a range of solutions for wound cleansing and moisturizing.